Germany · Delayed Price · Currency is EUR Revolution Medicines Statistics
Total Valuation
FRA:42Z has a market cap or net worth of EUR 12.61 billion. The enterprise value is 11.08 billion.
| Market Cap | 12.61B |
| Enterprise Value | 11.08B |
Important Dates
The next estimated earnings date is Thursday, February 26, 2026.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 193.32M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.98% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 2.37% |
| Owned by Institutions (%) | 93.38% |
| Float | 173.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 9.26 |
| P/TBV Ratio | 9.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -13.53 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.73 |
Financial Position
The company has a current ratio of 8.05, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.05 |
| Quick Ratio | 7.86 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -84.35 |
Financial Efficiency
Return on equity (ROE) is -60.76% and return on invested capital (ROIC) is -38.03%.
| Return on Equity (ROE) | -60.76% |
| Return on Assets (ROA) | -32.29% |
| Return on Invested Capital (ROIC) | -38.03% |
| Return on Capital Employed (ROCE) | -51.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.01M |
| Employee Count | 534 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -641,782 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +18.58% |
| 50-Day Moving Average | 48.77 |
| 200-Day Moving Average | 37.52 |
| Relative Strength Index (RSI) | 75.32 |
| Average Volume (20 Days) | 198 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.73 |
Income Statement
| Revenue | n/a |
| Gross Profit | -750.44M |
| Operating Income | -883.88M |
| Pretax Income | -819.68M |
| Net Income | -819.04M |
| EBITDA | -877.73M |
| EBIT | -883.88M |
| Earnings Per Share (EPS) | -4.43 |
Balance Sheet
The company has 1.65 billion in cash and 135.06 million in debt, giving a net cash position of 1.51 billion.
| Cash & Cash Equivalents | 1.65B |
| Total Debt | 135.06M |
| Net Cash | 1.51B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 1.36B |
| Book Value Per Share | 7.17 |
| Working Capital | 1.48B |
Cash Flow
In the last 12 months, operating cash flow was -649.28 million and capital expenditures -13.03 million, giving a free cash flow of -662.31 million.
| Operating Cash Flow | -649.28M |
| Capital Expenditures | -13.03M |
| Free Cash Flow | -662.31M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:42Z does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.98% |
| Shareholder Yield | -15.98% |
| Earnings Yield | -6.50% |
| FCF Yield | -5.25% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |